Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-223-0 | CAS number: 93-15-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- NTP Technical Report on the Toxicology and Carcinogenesis Studies of Methyleugenol (CAS No. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies) [Toxicokinetics]
- Author:
National Toxicology Program, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health- Year:
- 2 000
- Bibliographic source:
- NTP TR 491, NIH Publication No. 00-3950 [Online]. Available: https://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr491.pdf [cited April 13, 2015]
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
Test animals
- Species:
- other: rat and mouse
- Strain:
- other: F344/N and B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Summarized data for all three toxicokinetic studies: Single-administration intravenous and gavage study, gavage study in core study animals and single-dose toxicokintec study in aged animals:
TEST ANIMALS
- Source: Taconic Laboratory Animals and Services (Germantown, NY) and Charles River Laboratories (Portage, MI)
- Housing: Polycarbonate cages and hardwood bedding
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum):ad libitum
- Acclimation period: 11 days to 14 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): about 22°C
- Humidity (%): about 50%
- Air changes (per hr): minimum of 10/hour
- Photoperiod (hrs dark / hrs light): 12 hours/day
Administration / exposure
- Route of administration:
- other: oral gavage or intravenous
- Vehicle:
- methylcellulose
- Duration and frequency of treatment / exposure:
- PREPARATION OF DOSING SOLUTIONS:
- Single-administration intravenous and gavage study: Dose formulations for gavage administration were prepared in 0.5% aqueous methylcellulose. Dose formulations for intravenous injection were prepared by mixing methyleugenol with water:emulphor:ethanol (8:1:1). Dosing volume=4 mL/kg body weight (intravenous injection); Dosing volume=10 mL/kg body weight (gavage).
- Gavage study in core study animals and single-dose toxicokintec study in aged animals: The dose formulations were prepared by mixing methyleugenol with 0.5% aqueous methylcellulose to give the required concentrations. Dosing volume=5 mL/kg body weight (rats); Dosing volume=10 mL/kg body weight (mice)
VEHICLE
- Concentration in vehicle: 0.5% aqueous methylcellulose (for all three studies)
- Lot/batch no. (if required): 876672 and 946150 (only 876672 used in the single-administration intravenous and gavage study)
- Purity: USP/FCC grade (for all three studies)
Duration and frequency of treatment / exposure:
- Single-administration intravenous and gavage study: single dose
- Gavage study in core study animals: 5 days a week for 18 months
- Single-dose toxicokintec study in aged animals: 18 month undosed animals received a single dose
Doses / concentrations
- Remarks:
- Doses / Concentrations:
- Single-administration intravenous and gavage study: Intravenous injection of 37 mg methyleugenol/kg body weight; single dose of 37, 75, or 150 mg methyleugenol/kg body weight by gavage (rats) and a single intravenous injection of 25 mg methyleugenol/kg body weight or a single dose of 25, 50, or 75 mg methyleugenol/kg body weight by gavage (mice)
- Gavage study in core study animals: Administration of 37, 75, 150, or 300 mg/kg (rats) and administration of 37, 75 or 150 mg/kg (mice)
- Single-dose toxicokintec study in aged animals: Dose of 75 mg/kg (mice) or 150 mg/kg (rats)
- No. of animals per sex per dose / concentration:
- - Single-administration intravenous and gavage study: 12 male and 12 female rats; 24 male and 24 female mice
- Gavage study in core study animals: 10 male and 10 female rats and 10 male and 10 female mice
- Single-dose toxicokintec study in aged animals: 14 male and 15 female rats and 12 male and 14 female mice
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
Absorption (rats):
Absorption from oral doses was rapid, with peak plasma levels achieved within the first 5 minutes for all doses in males and females.
Absorption (mice):
Absorption from oral doses was rapid, with peak plasma levels achieved within the first 5 minutes for all doses in males and females.- Details on distribution in tissues:
- Distribution (rats):
Methyleugenol and its metabolites were distributed preferentially to the liver 72 hours after gavage or intravenous administration of [14C]-methyleugenol to males. Tissue:blood ratios of methyleugenol-derived radioactivity were 2 to 3 in the liver, 0.9 to 1.4 in the kidney, and significantly less than 1 in all other tissues examined after 72 hours.
Distribution (mice):
Methyleugenol and its metabolites were distributed preferentially to the ovaries, stomach, fat, spleen, and liver 72 hours after oral administration of [14C]-methyleugenol to males. Tissue:blood ratios of methyleugenol-derived radioactivity were approximately 5 in the liver, 5 to 9 in the stomach, 7 in the fat and the spleen, and over 100 in the ovaries after 72 hours. Many other tissues had elevated ratios; this may represent residual binding of metabolites rather than tissue solubility.
- Details on excretion:
Elimination (rats):
Approximately 85% of methyleugenol administered orally to males was eliminated in urine as parent or metabolites. Elimination of methyleugenol from the bloodstream was rapid and multiphasic, with initial half-lives on the order of 5 minutes and terminal half-lives on the order of 1 to 2 hours in males and females. No difference in the elimination of the parent compound between naive males and females was apparent with either young or aged animals. Male core study animals eliminated methyleugenol more rapidly at 6 and 12 months, with areas under the concentration versus time curve (AUCs) generally less than those for the naive animals. Females at all time points and males at 18 months had AUCs similar to those of naive animals. This suggests that metabolic induction may occur to a greater extent in males than in females. Plots of AUC versus dose were sublinear in males at 6 and 12 months, indicative of metabolic saturation at the higher doses at these time points, but approximately linear at 18 months. The increase in AUCs with age in the core study males and females is suggestive of an age-related decrease in methyleugenol metabolic capability.
Elimination (mice):
Elimination of methyleugenol from the bloodstream was rapid and multiphasic, with terminal half-lives in the order of 15 to 30 minutes. No difference in the elimination of methyleugenol between naive males and females was apparent with either young or aged animals. Aged females exhibited a significantly higher AUC; this may be due to differences in the amount of body fat or an age-related decrease in metabolic capability. Core study animals eliminated methyleugenol with AUCs similar to those of the naive animals. Exceptions were for the low-dose females. The AUCs increased linearly with dose in females at 12 months and sublinearly in males at 12 months. The latter finding is indicative of metabolic saturation at the higher doses in males at this time point.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Metabolism (rats):
Methyleugenol was rapidly metabolized. Approximately 85% of methyleugenol orally administered to males was eliminated in urine as metabolites by 72 hours after dosing. Bioavailability of methyleugenol was low in both males and females, with less than 6% bioavailability at 37 mg/kg. This increased to approximately 13% at 75 mg/kg and 15% to 20% at 150 mg/kg. These findings suggest a strong, but saturable, first-pass metabolic effect, leading to a nonlinear relationship between dose and parent chemical dosimetry. No parent methyleugenol was found in urine from males dosed with methyleugenol orally or by intravenous injection. Hydroxylated, sulfated, and glucuronidated metabolites constituted the majority of metabolites detected in urine.
Metabolism (mice):
Approximately 85% of methyleugenol orally administered to females was eliminated in urine as parent or metabolites by 72 hours after dosing. Bioavailability of methyleugenol was low, with 3% to 5% bioavailability at 25 mg/kg. This increased to approximately 12% at 50 mg/kg and 13% to 19% at 75 mg/kg. These findings suggest a strong, but saturable, first-pass metabolic effect, leading to a nonlinear relationship between dose and parent chemical dosimetry. No unchanged methyleugenol was found in urine from females dosed with methyleugenol orally. Hydroxylated, sulfated, and glucuronidated metabolites constituted a minority of the metabolites detected in urine, with the majority unknown.
Applicant's summary and conclusion
- Conclusions:
- Methyleugenol is rapidly absorbed following oral administration to rats and mice. The kinetic data are consistent with rapid clearance from the blood, metabolism in the liver, and excretion of the parent and various metabolites in the urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.